嘌呤核苷磷酸化酶
化学
小分子
嘌呤
白血病
癌症研究
药理学
生物化学
酶
免疫学
生物
作者
Yangyang Chen,Yang Li,Jing Gao,Quanwei Yu,Yiwen Zhang,Jifa Zhang
标识
DOI:10.1016/j.ejmech.2024.116437
摘要
As a cytosolic enzyme involved in the purine salvage pathway metabolism, purine nucleoside phosphorylase (PNP) plays an important role in a variety of cellular functions but also in immune system, including cell growth, apoptosis and cancer development and progression. Based on its T-cell targeting profile, PNP is a potential target for the treatment of some malignant T-cell proliferative cancers including lymphoma and leukemia, and some specific immunological diseases. Numerous small-molecule PNP inhibitors have been developed so far. However, only Peldesine, Forodesine and Ulodesine have entered clinical trials and exhibited some potential for the treatment of T-cell leukemia and gout. The most recent direction in PNP inhibitor development has been focused on PNP small-molecule inhibitors with better potency, selectivity, and pharmacokinetic property. In this perspective, considering the structure, biological functions, and disease relevance of PNP, we highlight the recent research progress in PNP small-molecule inhibitor development and discuss prospective strategies for designing additional PNP therapeutic agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI